June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Short Term Visual Related Ocular Side Effects During Treatment with D-MPH for ADHD
Author Affiliations & Notes
  • Gilad Fainberg
    Tel Aviv University, Tel Aviv, Israel
  • Yael Leitner
    Institute of Child Development, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    Pediatrics Department, Tel Aviv University, Tel Aviv, Israel
  • Dinah Zur
    Ophthalmology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    Ophthalmology Department, Tel Aviv University, Tel Aviv, Israel
  • Ainat Klein
    Ophthalmology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    Ophthalmology Department, Tel Aviv University, Tel Aviv, Israel
  • Daphna Mezad-Koursh
    Ophthalmology Division, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
    Ophthalmology Department, Tel Aviv University, Tel Aviv, Israel
  • Footnotes
    Commercial Relationships   Gilad Fainberg, None; Yael Leitner, None; Dinah Zur, None; Ainat Klein, None; Daphna Mezad-Koursh, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 2738. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Gilad Fainberg, Yael Leitner, Dinah Zur, Ainat Klein, Daphna Mezad-Koursh; Short Term Visual Related Ocular Side Effects During Treatment with D-MPH for ADHD. Invest. Ophthalmol. Vis. Sci. 2021;62(8):2738.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the short-term effect of dexmethylphenidate (D-MPH) on visual acuity, pupil size, anterior chamber depth (ACD), and accommodation-convergence reflex in children treated with D-MPH XR for attention-deficit/hyperactivity disorder (ADHD).

Methods : Prospective cohort study including 15 patients aged 8-16 (11.58±2.39) treated with D-MPH for ADHD. Patients were questioned for subjective complains such as blurred vision and photosensitivity. Ophthalmic evaluation was performed twice; prior to and 1.5 hours following D-MPH administration. The exam included evaluation of best corrected visual acuity at distance and near, accommodation range, convergence range, 3-D vision test and anterior chamber optical coherence tomography (OCT).

Results : A significant association between pupil diameter and D-MPH treatment dose was demonstrated (p=0.001). Additionally, a positive correlation between complains about blurred vision and D-MPH daily dosage was found. There were no significant changes in visual acuity, convergence range, stereo vision, accommodation range, or anterior chamber measures.

Conclusions : Our findings provide further support to the effect of stimulants on pupil diameter, as well as on subjective complains about blurred vision in a dose dependent manner. Additionally, future research is required to further investigate a potential role for pupil diameter as a marker of response to D-MPH.

This is a 2021 ARVO Annual Meeting abstract.

 

Imaging of the anterior chamber with Visante Anterior Chamber OCT (Carl Zeiss Meditec©). (a) Pupil diameter was measured as the distance between iris inner borders. (b) Anterior Chamber depth was measured as the distance, perpendicular to the angle-to-angle line, between the middle of the pupil and the inner edge of the corneal layer.

Imaging of the anterior chamber with Visante Anterior Chamber OCT (Carl Zeiss Meditec©). (a) Pupil diameter was measured as the distance between iris inner borders. (b) Anterior Chamber depth was measured as the distance, perpendicular to the angle-to-angle line, between the middle of the pupil and the inner edge of the corneal layer.

 

Correlation between D-MPH dosage and change in pupil diameter. ANOVA analysis of pupil diameter change per dosage group of D-MPH treatment, 10 mg (Low), 10-20 (Moderate) and 25-30 (High). Data is presented as mean ± SD and ANOVA analysis parameters presented below.

Correlation between D-MPH dosage and change in pupil diameter. ANOVA analysis of pupil diameter change per dosage group of D-MPH treatment, 10 mg (Low), 10-20 (Moderate) and 25-30 (High). Data is presented as mean ± SD and ANOVA analysis parameters presented below.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×